Prostate-specific membrane antigen and other prostatic tumor markers on the horizon

Urologic Clinics of North America

Volumn 24, Issue 2, 1997, Pages 439-450

  Israeli, R S ^a   Grob, M ^a   Fair, W R ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; ANDROGEN RECEPTOR; GLYCOPROTEIN; HYALURONIDASE; MEMBRANE ANTIGEN; MESSENGER RNA; NUCLEAR PROTEIN; ONCOPROTEIN; PROSTATE SPECIFIC ANTIGEN; PROTEIN BCL 2; PROTEIN P53; TELOMERASE; TUMOR MARKER; UVOMORULIN;

ALTERNATIVE RNA SPLICING; ANTIGEN DETECTION; CHROMOSOMAL LOCALIZATION; CHROMOSOME 11; GENE MAPPING; HUMAN; IMMUNOSCINTIGRAPHY; MOLECULAR WEIGHT; NONHUMAN; ONCOGENE C ERB; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN STRUCTURE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; TUMOR SUPPRESSOR GENE;

EID: 0030938509     PISSN: 00940143     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0094-0143(05)70391-8     Document Type: Article

References (79)

1. H. Abdel-Nabi G.L. Wright J.V. Gulfo Monoclonal antibodies and radioimmunoconjugates in the diagnosis and treatment of prostate cancer Semin Urol 10 1992 45 54
2. J. Adenoro L. Madewell M. Kattan Prognostic value of immunohistochemical staining for E-cadherin and a-catenin expression on prostate needle biopsies [abstract 959] J Urol 155 1996 550A
3. A.G. Aprikian A.S. Sarkis W.R. Fair Immunohistochemical determination of p53 protein accumulation in prostatic adenocarcinoma J Urol 151 1994 1276 1280
4. O.A. Armas A.G. Aprikian J. Melamed Clinical and pathobiological effects of neoadjuvant total androgen ablation therapy on clinically localized prostatic adenocarcinoma Am J Surg Pathol 18 1994 979 991
5. 90Y-CYT-356, a new prostatic cancer therapeutic agent [abstract] J Urol 147 1992 361A
6. 111Indium-labeled monoclonal antibody CYT-356 J Urol 152 1994 1952 1955
7. J.J. Bauer I.A. Sesterhenn F.K. Mostofi Elevated levels of apoptosis regulator proteins 53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer patients [abstract 964] J Urol 155 1996 552A
8. M.L. Beckett G.B. Lipford C.L. Haley Monoclonal antibody PD-41 recognizes an antigen restricted to prostate adenocarcinomas Cancer Res 51 1991 1326 1333
9. J.D. Brooks S. Bova C.M. Ewing p53 alterations do not predict recurrence in primary human prostate cancers J Urol 155 1996 552A
10. M.J.G. Bussemakers A. Van Bokhoven N. Ru DD3: A new prostate specific marker, over-expressed in prostate tumors [abstract 3522] Proceedings of the American Association for Cancer Research 37 1996 515
11. C. Cama C.A. Olsson A.J. Raffo Molecular staging of prostate cancer: II. A comparison of the application of an enhanced reverse transcriptase polymerase chain reaction assay for prostate specific antigen versus prostate specific membrane antigen J Urol 153 1995 1373 1378
12. L. Cannon D.T. Bishop M. Skolnick Genetic epidemiology of prostate cancer in the Utah Mormon genealogy Cancer Surv 1 1982 47 69
13. R.E. Carter A.R. Feldman J.T. Coyle Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase Proc Natl Acad Sci U S A 93 1996 749
14. F. Chang S. Syrjanen K. Syrjanen Implications of the p53 tumor-suppressor gene in clinical oncology J Clin Oncol 13 1995 1009 1022
15. M. Colombel F. Symmans S. Gil Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone-refractory human prostate cancers Am J Pathol 143 1993 390 400
16. J.G. Corr R.S. Israeli R.F. Huryk Prostate specific membrane antigen (PSM) expression in orthotopically implanted human prostate cancer cells in nude mice slows tumor growth and metastatic potential [abstract] J Urol 151 1994 492A
17. S.M. Diamond W.R. Fair G.J. Wise Modulation of prostate specific membrane antigen (PSM) expression in-vitro by cytokines and growth factors [abstract] J Urol 153 1995 382A
18. J.T. Dong P.W. Lamb C.W. Rinker-Schaeffer KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2 Science 268 1995 884 886
19. D.F. Easton D.T. Bishop D. Ford Genetic linkage analysis in familial breast and ovarian cancer: Results from 214 families Am J Hum Genet 52 1992 678 701
20. W.R. Fair R.S. Israeli Y. Wang Neoadjuvant androgen-deprivation therapy (ADT) prior to radical prostatectomy results in a significantly decreased incidence of residual micrometastatic disease as detected by nested RT-PCR with PSM primers J Urol 153 1995 391A
21. Q. Feng M.L. Beckett P. Kaladas Purification and biochemical characterization of the 7E11-C5 prostate carcinoma-associated antigen [abstract] Proceedings of the American Association for Cancer Research 32 1991 239
22. D. Ford D.F. Easton D.T. Bishop Risks of cancer in BRCA1-mutation carriers Lancet 343 1994 692 695
23. P. Henttu S. Liao P. Vihko Androgens up-regulate the human prostate-specific antigen messenger ribonucleic acid (mRNA), but downregulate the prostatic cid phosphatase mRNA in the LNCaP cell line Endocrinology 130 1992 766 772
24. D. Hockenbery G. Nunez C. Milliman Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death Nature 348 1990 334 336
25. J.S. Horoszewicz E. Kawinski G.P. Murphy Monoclonal antibodies to a new antigenic marker in epithelial cells and serum of prostatic cancer patients Anticancer Res 7 1987 927 936
26. J.S. Horoszewicz S.S. Leong E. Kawinski LNCaP model of human prostatic carcinoma Cancer Res 43 1983 1809 1818
27. J.H. Hughes M.B. Cohen R.A. Robinson p53 immunoreactivity in primary and metastatic prostatic adenocarcinoma Mod Pathol 8 1995 462 466
28. T. Ichikawa Y. Ichikawa J. Dong Localization of metastasissuppressor gene(s) for prostatic cancer to the short arm of human chromosome 11 Cancer Res 52 1992 486 490
29. R.S. Israeli W.H. Miller S.L. Su Sensitive detection of prostatic hematogenous micrometastases using PSA and PSM-derived primers in the polymerase chain reaction J Urol 153 1995 573 577
30. R.S. Israeli W.H. Miller Jr S.L. Su Sensitive nested RT-PCR detection of circulating prostatic tumor cells: Comparison of PSM and PSA-based assays Cancer Res 54 1994 6306 6310
31. R.S. Israeli C.T. Powell J.G. Corr Expression of the prostate-specific membrane antigen Cancer Res 54 1994 1807
32. R.S. Israeli C.T. Powell W.R. Fair Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen Cancer Res 53 1993 227
33. R.S. Israeli C.W. Rinker-Schaeffer C.T. Powell Localization of the prostate specific membrane antigen (PSM) to the putative metastasis suppressor region on human chromosome 11 [abstract] J Urol 151 1994 252A
34. R.S. Israeli C.W. Rinker-Schaeffer C.T. Powell Localization of the prostate specific membrane antigen (PSM) to the putative metastasis-suppressor region on human chromosome 11 [abstract] Proceedings of the American Association for Cancer Research 35 1994 271
35. 111Indium labeled CYT-356 for the detection of occult prostate cancer recurrence J Urol 152 1994 1490 1495
36. W.P. Keer J.M. Koslowski Y.C. Tsai Elevated transferrin receptor content in human prostate cancer cell lines assessed in vitro and in vivo J Urol 143 1990 381 385
37. E.J. Kuhn R.A. Kurnot I.A. Sesterhenn Expression of the c-erbB-2 (HER-2/neu) oncoprotein in human prostatic carcinoma J Urol 150 1993 1427 1433
38. F. Labrie L. Cusan J.L. Gomez Downstaging by combination therapy with flutamide and an LHRH agonist before radical prostatectomy Cancer Surv 23 1995 149 156
39. B.R. Lee A.W. Partin R.H. Getzenberg PC-1: A novel nuclear matrix protein in human prostate cancer but not BPH or normal prostate: Further characterization [abstract] J Urol 151 1994 252A
40. J. Leek N. Lench B. Maraj Prostate-specific membrane antigen: Evidence for the existence of a second related human gene Br J Cancer 72 1995 583 588
41. V.B. Lokeshwar B.L. Lokeshwar H.T. Pham Association of elevated levels of hyaluronidase, a matrix-degrading enzyme, with prostate cancer progression Cancer Res 56 1996 651 657
42. A.D. Lopes W.L. Davis M.J. Rosenstraus Immunohistochemical and pharmacokinetic characterization of the site-specific immunoconjugate CYT-356 derived from antiprostate monoclonal antibody 7E11-C5 Cancer Res 50 1990 6423 6429
43. A. Lundwall H. Lilja Molecular cloning of a human prostate specific antigen cDNA FEBS Lett 214 1987 317
44. A.K. Meeker J. Sauvageot D.S. Coffey Telomerase activity is a diagnostic marker for human prostate cancer and is applicable to needle biopsies [abstract 1533] J Urol 155 1996 694A
45. J. Mendelsohn Anti-EGF receptor monoclonal antibodies: Biological studies and potential clinical applications Trans Am Clin Climatol Assoc 100 1988 31 38
46. W.H. Miller Jr K. Levine A. DeBlasio Detection of minimal residual disease in acute promyelocytic leukemia by a reverse transcription polymerase chain reaction assay for the PML/RAR-α fusion mRNA Blood 82 1993 1689 1694
47. Y. Miyajima K. Kato S. Numata Detection of neuroblastoma cells in bone marrow and peripheral blood at diagnosis by the reverse transcriptase-polymerase chain reaction for tyrosine hydroxylase mRNA Cancer 75 1995 2757 2761
48. B.T. Montgomery C.Y.F. Young D.C. Bilhartz Hormonal regulation of prostate specific antigen glycoprotein in the human adenocarcinoma cell line, LNCaP Prostate 21 1992 63 73
49. J.G. Moreno C.M. Croce R. Fischer Detection of hematogenous micrometastasis in patients with prostate cancer Cancer Res 52 1992 6110 6112
50. G.P. Murphy E.H. Holmes A.L. Boynton Comparison of prostate specific antigen, prostate specific membrane antigen, and LNCaP-based enzyme-linked immunosorbent assays in prostatic cancer patients and patients with benign prostatic enlargement Prostate 26 1995 164 168
51. G. Murphy H. Ragde G. Kenny Comparison of prostate specific membrane antigen, and prostate specific antigen levels in prostatic cancer patients Anticancer Res 15 1995 1473 1479
52. R.B. Myers S. Srivastava D.K. Oelschlager Expression of p160erbB-3 and p185erbB-2 in prostatic intraepithelial neoplasia and prostatic adenocarcinoma J Natl Cancer Inst 86 1994 1140 1145
53. K.R. Newhall J.T. Isaacs G.L. Wright Jr Dunning rat prostate tumors and cultured cell lines fail to express human prostate carcinoma-associated antigens Prostate 17 1990 317 325
54. G.D. Parks R.A. Lamb Topology of eukaryotic type II membrane proteins: Importance of N-terminal positively charged residues flanking the hydrophobic domain Cell 64 1991 777 787
55. A.J. Raffo H. Perlman M. Chen Over-expression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo Cancer Res 55 1995 4438 4445
56. C.W. Rinker-Schaeffer A.L. Hawkins S.L. Su Localization and physical mapping of the prostate specific membrane antigen (PSM) gene to human chromosome 11 Genomics 30 1995 105
57. Y.P. Rochon J.S. Horoszewicz A.L. Boynton Western blot assay for prostate-specific membrane antigen in serum of prostate cancer patients Prostate 25 1994 219 223
58. M.C. Rossi B.R. Zetter Selective stimulation of prostatic carcinoma cell proliferation by transferrin Proc Natl Acad Sci U S A 89 1992 6197 6201
59. Silver DA, Drobnjak M, Charytonowicz E, et al: Altered expression of cell-cycle regulatory proteins in human prostate cancer. Fourth Annual SPORE Investigators Meeting, Rockville, MD, July 1996.
60. M. Sokoloff C.L. Tso R. Kaboo Quantitative polymerase chain reaction does not improve prostate cancer staging: A clinical-pathologic-molecular analysis of 121 patients J Urol 156 1996 1560 1566
61. M.S. Soloway R. Sharifi Z. Wajsman Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxMo) prostate cancer: The Lupron depot neoadjuvant prostate cancer study group J Urol 154 1995 424 428
62. H. Sommerfeld A.K. Meeker M.A. Piatyszek Telomerase activity: A prevalent marker of malignant human prostate tissue Cancer Res 56 1996 218 222
63. J.J. Starling S.M. Sieg M.L. Beckett Human prostate antigens defined by murine monoclonal antibodies Cancer Res 46 1986 367 374
64. S.L. Su I.P. Huang W.R. Fair Alternatively spliced variants of prostate-specific membrane antigen RNA: Ratio of expression as a potential measurement of progression Cancer Res 55 1995 1441 1443
65. J.K. Troyer G.L. Wright Jr Biochemical characterization and mapping of the 7E11-C5.3 epitope of the prostate specific membrane antigen (PSMA) [abstract] J Urol 153 1995 381A
66. J.K. Troyer M.L. Beckett G.L. Wright Jr Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids Int J Cancer 62 1995 552
67. J.K. Troyer Q. Feng M.L. Beckett Biochemical characterization and mapping of the 7E11-C5.3 epitope of the prostate-specific membrane antigen Urologic Oncology 1 1995 29 37
68. H. Tulinius V. Egilsson G.H. Olafsdottir Risk of prostate, ovarian and endometrial cancer among relatives of women with breast cancer BMJ 305 1992 855 857
69. R. Umbas W.B. Isaacs P.P. Bringuier Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer Cancer Res 54 1994 3929 3933
70. R.W. Veltri A.W. Partin M.C. Miller Ability of DNA ploidy, HER-2/neu, chromagranin-A, CD-31, Ki67, and bcl-2 cellular biomarkers to predict prostate cancer progression [abstract 963] J Urol 155 1996 551A
71. G. von Heijne Transcending the impenetrable: How proteins come to terms with membranes Biochimica et Biophysica Acta 947 1988 307 333
72. D.C. West I.N. Hampson F. Arnold Angiogenesis induced by degradation products of hyaluronic acid Science 228 1985 1324 1326
73. B.J. Williams E. Jones X.L. Zhu Evidence for a tumor suppressor gene distal to BRCA1 in prostate cancer J Urol 155 1996 720 725
74. P.A. Wingo T. Tong D. Bolden Cancer statistics, 1995 CA Cancer J Clin 45 1995 8 30
75. G.L. Wright Jr M.L. Beckett G.B. Lipford A novel prostate carcinoma-associated glycoprotein complex (PAC) recognized by monoclonal antibody TURP-27 Int J Cancer 47 1991 717 725
76. G.L. Wright C. Haley M.L. Beckett Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues Urologic Oncology 1 1995 18 28
77. G.L. Wright Jr C.L. Haley Z. Csapo Immunohistochemical evaluation of the expression of prostate tumor-association markers in the nude mouse human prostate carcinoma heterotransplant lines PC-82, PC-EW, and PC-EG Prostate 17 1990 301 316
78. A. Wu J. Ben-Ezra A. Colombero Detection of micrometastasis in breast cancer by the polymerase chain reaction Lab Invest 62 1990 109A
79. G. Yang A.M.F. Stapleton T.M. Wheeler Clustered p53 immunostaining: A novel pattern associated with prostate cancer progression [abstract 965] J Urol 155 1996 552A